Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age25-75
SponsorFudan University
About this trial
The purpose of this study is to evaluate the clinical efficacy and safety of Cnidium Monnieri Detoxification Formula in clearing HPV infection, improving clinical symptoms and quality of life in female patients with persistent cervical high-risk HPV infection.
Eligibility criteria
Qualifiers
Age ≥ 25 years to ≤ 75 years，with sexual life history
Meet the diagnostic criteria for high-risk human papillomavirus (HR-HPV) persistent infection
After surgery or physical therapy for high-grade squamous intraepithelial lesions (HSIL) of the cervix or high-grade squamous intraepithelial lesions (VaINIII) of the vagina, or radical surgery for cervical/vaginal cancer or radical chemoradiotherapy, the examination remained positive for HR-HPV ≥6 months after the end of treatment, with the same type or multiple types as before treatment, and no progression or recurrence of the disease.
No local or systemic therapy has been administered to patients in the last 3 months
Disqualifiers
Only low-risk HPV infection
Colposcopy for high-grade intraepithelial lesions or cancer of the cervix, vagina, vulva, who have not received or are receiving treatment
Immunocompromised or immunosuppressant
Pregnant and lactating women
Trial design
Treatments tested in this trial
- Cnidium Monnieri Detoxification Formula
Treatment groups
79 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov